Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Key Moments:

  • Moderna (NASDAQ:MRNA) has fallen 16.8% this week to $206.80, while Amneal Pharmaceuticals (NASDAQ:AMRX) has climbed 63.72% since ProPicks AI highlighted it at $12.90.
  • Amneal raised full-year guidance for the third time on November 3, targeting revenue of $3.15 billion to $3.25 billion and adjusted EBITDA of $800 million to $815 million.
  • InvestingPro’s Fair Value estimate of $17.16 per share sits below Amneal’s $21.12 stock price and below Wall Street’s median 12-month target of $24.29.

Generics Specialist Quietly Outperforms as High-Profile Biotech Slips

While many well-known biotech and pharmaceutical names have struggled to hold gains in November, Amneal Pharmaceuticals (NASDAQ:AMRX) has delivered a markedly different performance. Moderna (NASDAQ:MRNA) has dropped 16.8% this week to $206.80, and InvestingPro still identifies the stock as 38.1% overvalued even after that decline.

In contrast, Amneal, a specialty and generic drug manufacturer focused on complex injectables, biosimilars, and branded therapies, is trading at $21.12, up 63.72% from the $12.90 level at which InvestingPro’s ProPicks AI selected it on June 1. The company has advanced by emphasizing products that are already approved and generating revenue, rather than relying on binary pipeline outcomes.

Amneal is on pace to achieve its seventh straight year of both revenue and earnings growth and on November 3 raised its full-year outlook for the third time. Over time, it has redirected its generics portfolio toward more complex, higher-barrier offerings.

ProPicks AI and the Mid-Cap Movers Strategy

Identifying when a mid-cap pharmaceutical company’s new approvals begin to flow through to the income statement is central to ProPicks AI’s design. Within InvestingPro’s Mid-Cap Movers strategy, which targets promising mid-cap businesses, Amneal has emerged as the leading gainer of 2026.

The strategy holds Amneal alongside a range of other notable performers across different sectors, including an HR outsourcing firm, a discount furniture retailer, and an enterprise technology services company.

Focus on Complex Generics and Limited-Competition Products

Amneal generates a substantial portion of its revenue from complex generics, injectables, and biosimilars that are difficult to produce and slow to secure regulatory approval. These characteristics typically limit the number of rivals for each product. The company holds the largest number of Competitive Generic Therapy approvals – an FDA designation granted to generics with minimal or no competition – in the U.S. pharmaceutical space.

Within its Affordable Medicines segment, non-oral solid products have increased from 35% of the mix in 2019 to 59% in 2026. The August acquisition of Kashiv’s biosimilar operations provided Amneal with fully integrated capabilities across research and development, manufacturing, and commercialization, and allows it to capture 100% of the profits from generic lanreotide.

Lanreotide as a Proof Point

The trajectory of lanreotide illustrates Amneal’s model. The FDA granted approval for the company’s generic version of Somatuline Depot on September 18, alongside a Competitive Generic Therapy designation. Amneal moved immediately to launch the drug, supported by in-house, large-scale manufacturing capacity.

Somatuline Depot generated $983 million in U.S. sales over the 12 months through July 2026. Lanreotide contributed about $7 million in Amneal’s third quarter, and management anticipates a multiple of that amount in the fourth quarter, with a targeted market share of 30% to 40%.

Third-Quarter Financial Performance and Updated Guidance

Third-quarter results indicate that the strategic push into complex products is impacting profitability. Revenue increased 10% year-over-year to $862.7 million, exceeding the consensus estimate of $812.1 million. Adjusted EPS came in at $0.26, up 53% and ahead of expectations of $0.23.

Adjusted EBITDA rose 30% to $207 million, with margin expanding by 370 basis points to 24.0%. Based on this performance, management raised full-year guidance, now projecting:

MetricUpdated 2026 Guidance
Revenue$3.15 billion – $3.25 billion
Adjusted EBITDA$800 million – $815 million
Adjusted EPS$1.04 – $1.08

However, cash generation has lagged. Amneal cut its operating cash flow outlook to a range of $325 million to $375 million, down from $350 million to $400 million. The company attributed this to a deliberate inventory buildup for growth products and receivables that are now expected to be collected in the first quarter of 2027.

The Kashiv acquisition pushed net leverage to 3.0 times adjusted EBITDA at the end of the third quarter. Management expects leverage to reach 3.6 times by year-end, with a goal of bringing it below 3 times by 2028.

Valuation Tension: Wall Street vs Fair Value Models

ProPicks AI added Amneal to the Mid-Cap Movers strategy on June 1, more than three months ahead of the lanreotide approval and five months before the third upward guidance revision. Since then, research coverage has increasingly reflected the improved outlook.

FirmRatingTarget Price
JPMorganBuy$25
UBSBuy$25
OppenheimerBuy$27
LeerinkBuy$23
Piper SandlerBuy$21
DA DavidsonHoldNot specified

The median 12-month price target stands at $24.29, within a range of $20 to $28, and above the current $21.12 share price. Analyst forecasts call for EPS to increase from $1.04 in fiscal 2026 to $1.28 in fiscal 2027 and $1.50 in fiscal 2028, implying a multiple of about 20.3 times this year’s earnings estimate.

InvestingPro’s Fair Value models, however, point to an intrinsic value of $17.16 per share. This sits below the current market price and well under the Street’s median target, making Fair Value the more conservative reference point. The stock currently trades within 5% of its 52-week high of $22.10.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News